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a b s t r a c t
Hepatitis B virus (HBV) infection is a major public health problem. Recently, the human liver bile acid
transporter Naþ/taurocholate cotransporting polypeptide (NTCP) has been identiﬁed as an HBV speciﬁc
receptor. NTCP expression is known to be strongly regulated by IL-6. This study was aimed at
characterizing the effect of IL-6 on HBV entry. HBV entry was inhibited by up to 90% when cells were
pretreated with IL-6 as shown by a strong inhibition of long term HBsAg secretion. This effect was
conﬁrmed by showing a severe reduction of intracellular HBV cccDNA. In parallel, we observed a 98%
decrease in NTCP mRNA steady state level and an 80% reduction in NTCP-mediated taurocholate uptake.
IL-6-mediated inhibition of NTCP-mediated taurocholate uptake and viral entry exhibited similar dose-
dependence and kinetics while restoration of NTCP expression suppressed the inhibitory effect of IL-6.
NTCP-mediated HBV entry is therefore markedly inhibited by IL-6.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Hepatitis B virus (HBV) infection is still a major public health
problem worldwide. HBV is a small enveloped, double-strand DNA
virus belonging to the Hepadnaviridae family that causes acute and
chronic hepatitis B. Chronic HBV carriers have an elevated risk to
develop cirrhosis and hepatocellular carcinoma (Seeger and Mason,
2000). Upon viral infection, an early innate response is induced to
limit viral replication, then an adaptive speciﬁc immune response is
mounted allowing virus elimination. In the case of HBV, the early
innate response was thought to be absent or very faint, virus being
eliminated by the effectors of a strong adaptive response which acted
ﬁrst by a non cytopathic effect of cytokines, mostly driven by gamma
interferon (IFN)-γ, then by a cytolytic effect (Wieland and Chisari,
2005). However, patients with acute or fulminant HBV infection have
elevated levels of proinﬂammatory cytokines, with gradual increase in
the serum levels of IL-6 (Sekiyama et al., 1994; Sun et al., 1992; Torre
et al., 1994) while elevated IL-6 concentration was found to correlate
with acute exacerbation of chronic hepatitis B (Wu et al., 2014).
Nevertheless, compared to HCV or HIV, HBV infection does moder-
ately induce cytokine secretion (Stacey et al., 2009). A recent study
with 2 human patients provides us with a clear evidence that the
innate immune system is able to sense HBV infection which probably
contribute to contain HBV infection and to allow timely induction of
adaptive response (Fisicaro et al., 2009).
Interestingly, in primary human hepatocyte cultures it has been
shown that HBV infection induced an innate response in contam-
inating non-parenchymal cells, essentially kupffer cells, with a pic
of cytokine secretion, mainly IL-6, which in turn down regulates
viral transcription in infected hepatocytes (Hösel et al., 2009).
Although the effect of IL-6 on HBV transcription was ﬁnely
detailed in this study no inﬂuence of IL-6 treatment on HBV entry
was reported.
Despite considerable efforts, HBV cell entry mechanisms remained
poorly deﬁned for many years. We have previously demonstrated that
a peptide corresponding to the N-terminal part of the pre-S1 region of
large envelope protein prevented HBV infection (Gripon et al., 2005).
Recently the target of this peptide was identiﬁed by Yan and
collaborators as NTCP (Yan et al., 2012) which is now widely
recognized as the main HBV receptor (Urban et al., 2014). Here, we
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focused our work on the effect of IL-6 on HBV entry since NTCP is
known to be strongly down regulated by IL-6 in primary human
hepatocytes and HepaRG cells (Le Vee et al., 2009b); (Klein et al.,
2015). We report here that IL-6 strongly inhibits HBV entry by down
regulation of NTCP receptor.
Results
IL-6 inhibits NTCP expression and HBV entry in a dose-dependent
manner
For studying HBV entry we have used 2 in vitro HBV infection
models. The most ancient relies on primary human hepatocytes
was originally developed by us (Gripon et al., 1993, 1988). This
model has been shown very interesting for the analysis of the
factors inﬂuencing viral entry (Le Seyec et al., 1998; Lepère-Douard
et al., 2009; Maeng et al., 2000). Since PHH availability is very
limited we have also used a second model, the HBV infection of
HepaRG cell line, that we have developed more recently (Gripon
et al., 2002) and which has been largely used for clarifying HBV
entry (Macovei et al., 2010; Schulze et al., 2012, 2007). The
presence of functional NTCP on cell plasma membrane was
evaluated by measuring NTCP-mediated taurocholate uptake,
whereas HBV entry was measured by quantifying secreted HBsAg
day 11 post-infection. Since HBsAg release from the inoculum is
transient and limited the secreted HBsAg detected long after
infection reﬂects the amount of cccDNA provided that transcrip-
tion and translation of this gene are not differentially affected by
culture conditions and therefore constitute a quantiﬁable and
reliable marker of viral entry as demonstrated in several studies
(Gripon et al., 2002, 1995, 1993, 1988; Maeng et al., 2000). Indeed
Maeng et al. (2000) performing HBV neutralization assays showed
an excellent correlation between long term HBsAg secretion and
intracellular viral DNA, while another study showed a perfect
correlation between long term HBsAg secretion and cccDNA in the
analysis of HBV mutants bearing short deletions in preS1 region of
the large envelope protein (Le Seyec et al., 1999). We have veriﬁed
that long term HBsAg secretion was not affected by an IL-6 pre-
treatment. Indeed when cells are treated with IL-6 after HBV
infection, the HBsAg production although initially inhibited by
IL-6, as expected from the known effect of IL-6 on HBV transcrip-
tion (Hösel et al., 2009) returned to the control level within 9 days
post-treatment Fig. 1A). HBV entry measured by long term HBsAg
secretion is expressed as percentage compared to 100% of infec-
tion in non-treated cells, taking in consideration infection level
variation between experiments. In general, HBsAg concentration
varied between 25 and 40 ng/ml in the supernatants of infected
HepaRG and PHH control cells.
We ﬁrst conﬁrmed that IL-6 does not induce any toxicity after
4 days of treatment (Fig. 1B). We then investigated the effect of a
concentration range of IL-6 on NTCP-mediated taurocholate
uptake and HBV entry. Cells were pre-treated for 72 h with doses
of IL-6 from 0.15 to 10 ng/ml, the medium being renewed daily.
HBV infection was then performed in the presence of IL-6 for 16 h
(Fig. 2A). After washing out free HBV, cells were further cultured
for 11 days in the absence of IL-6 (Fig. 2A). In HepaRG cells, IL-6 at
0.15 ng/ml inhibited NTCP-mediated taurocholate uptake by 41%
(po0.0001); this inhibition reached 71% (po0.0001) at 10 ng/ml
(Fig. 2B). HBV entry was efﬁciently inhibited as well, up to 71%
(po0.0001) at 0.15 ng/ml, reaching 92% (po0.0001) at 10 ng/ml
(Fig. 2C). Moreover, NTCP mRNA level measured by RTqPCR
showed a maximal reduction of 97% (po0.0001) at 10 ng/ml
(Fig. 2D). This effect of IL-6 on sodium-dependent taurocholate
transport, HBV entry and NTCP mRNA level was not limited to
HepaRG cells, as we observed a similar effect of IL-6 on PHH even
though it was less pronounced. In PHH, IL-6 inhibits NTCP-related
taurocholate uptake by 57% (po0.0001) at 10 ng/ml (Fig. 2E).
Similarly, HBV entry was inhibited by 78% (po0.0001) at 10 ng/ml
(Fig. 2F). A very strong inhibition of NTCP mRNA expression was
however observed with the 2 cellular models already reaching 80%
(po0.0001) at 0.15 ng/ml suggesting a major regulation at the
transcription level of NTCP (Fig. 2D and G). These data suggest that
there is a dose-dependent IL-6 inhibition of NTCP expression and
viral entry in HepaRG cells and PHH. A strong correlation between
inhibition of NTCP-mediated taurocholate uptake and HBV entry
inhibition was observed. In addition the IL-6 dose of 10 ng/ml was
the optimal dose for a strong HBV entry inhibition.
IL-6 inhibits NTCP expression and HBV entry in a time-dependent
manner
In order to better characterize the IL-6 effect, a time response
study was carried out. HepaRG cells and PHH were treated with
10 ng/ml of IL-6 for 0 h, 24 h, 48 h, or 72 h before a 16 h HBV
infection performed in the presence of IL-6 (Fig. 3A). Sodium-
dependent taurocholate uptake, HBV entry and NTCP mRNA
levels were evaluated as mentioned above. Inhibition of NTCP-
mediated taurocholate transport was evidenced with a signiﬁ-
cant reduction after a 24 h treatment in HepaRG cells and PHH
but maximum inhibition occurred only after 72 h reaching 78%
(po0.0001) in HepaRG cells, and 55% (po0.0001) in PHH
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Fig. 1. Effect of a post-infection IL-6 treatment and IL-6 cytotoxicity on HepaRG cells. (A) HepaRG cells were infected with HBV for 16 h. After washing cells were treated for
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(Fig. 3B and F). After 72 h of treatment, HBV entry was inhibited
by 90% (po0.0001) in HepaRG cells, and by 77% (po0.0001) in
PHH (Fig. 3C and G). Then, HBV entry inhibition correlated with
inhibition of NTCP-mediated taurocholate uptake in HepaRG and
PHH. By contrast, in HepaRG cells, NTCP mRNA level drastically
decreased much earlier since a 24 h treatment led to a 94%
inhibition (Fig. 3D). The same drastic drop in NTCP mRNA level
was observed within 24 h in PHH (data not shown). Given this
very rapid and drastic down regulation of NTCP transcripts after
IL-6 treatment, the delayed effect on NTCP protein-mediated
taurocholate accumulation was likely due to a great stability of
the NTCP protein. These data show again a correlation between
the decrease of NTCP-mediated taurocholate transport and the
HBV entry inhibition. This inhibitory effect is likely consecutive
to a down-regulation of the steady state level of NTCP mRNAs.
IL-6 inhibits cccDNA formation in a time-dependent manner
cccDNA results from intracellular maturation of the HBV DNA
present in infectious viral particles and is the matrix of viral
transcription. Formation of cccDNA in the nucleus is achieved 4 days
post-infection and reﬂects the early steps of infection, i.e., the viral
entry (Gripon et al., 1993). Quantiﬁcation of cccDNA was a comple-
ment of the HBsAg quantiﬁcation for HBV entry evaluation. HepaRG
cells were treated with 10 ng/ml of IL-6 for 24 h, 48 h, or 72 h before
HBV infection in the presence of IL-6 (Fig. 3A). cccDNA quantiﬁcation
was done by a speciﬁc qPCR method. Our results show that the
amount of cccDNA in infected cells was decreased by 90% after 72 h
of IL-6 treatment compared to non-treated infected cells (Fig. 3E).
Thus this speciﬁc and direct evaluation of HBV cccDNA did fully
conﬁrm that IL-6 efﬁciently inhibits HBV entry.
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Exogenous expression of NTCP suppresses the inhibitory effect of IL-6
To demonstrate that the effect of IL-6 on viral entry was
mediated by NTCP, HepaRG cells were infected with lentiviral
particles in order to overexpress an exogenous NTCP receptor. This
vector is made of a NTCP gene linked by a P2A sequence to a
mCherry ﬂuorescent protein placed under the control of a CMV
promoter (vector NTCP-P2A-mCherry). Exogenous NTCP expression
was evaluated by measurement of mCherry ﬂuorescence level since
both proteins are expected to be produced in equimolar amounts
(Kim et al., 2011). We observed that mCherry ﬂuorescence remained
unchanged after IL-6 treatment, showing that the CMV promoter
activity was not affected by IL-6 (data not shown). HepaRG cells
were then infected with lentiviral particles 2 days before a 3 days IL-
6 treatment. Cells were then infected by HBV in the presence of IL-6
(Fig. 4A). In cells transduced with NTCP P2A mCherry, NTCP-
mediated taurocholate uptake reached about tenfold the endogen-
ous accumulation level while the HBV infection was twice as
efﬁcient as in the mCherry control (Fig. 4B and C). Under these
conditions, IL-6 did no longer affect either sodium-dependent
taurocholate accumulation or HBV infection, while this IL-6 treat-
ment strongly down-regulated the activity of endogenous NTCP-
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mediated taurocholate uptake and inhibited viral entry in control
cells (Fig. 4B and C). Since IL-6 has no effect on HBV entry when
NTCP level is maintained, we can conclude from our experiment that
IL6 controls HBV entry only through down-regulation of NTCP
receptor.
Reversibility of the IL-6 effect
Our data indicated that IL-6 strongly down-regulates NTCP
mRNA expression resulting in a signiﬁcant inhibition of NTCP-
mediated taurocholate accumulation and HBV entry. To better
characterize the IL-6 effect, it seemed important for us to examine
whether it was reversible. HepaRG cells were treated or not with
IL-6 for 72 h, then infected 0 h, 24 h, 48 h, or 72 h post-treatment
without IL-6 (Fig. 5A). An optimal inhibitory effect occurred
immediately after IL-6 treatment (0 h), with an 80% inhibition of
sodium-dependent taurocholate accumulation and a 90% inhibi-
tion of HBV entry. By contrast, 72 h after IL-6 withdrawal, NTCP-
mediated taurocholate accumulation returned to the normal level
and viral entry was completely restored (Fig. 5B and C). These data
suggest that IL-6 acts temporarily on NTCP-related taurocholate
inﬂux and HBV entry and excludes that any irreversible effect such
as apoptosis may explain the observed inhibition of HBV infection.
Discussion
In this study we demonstrate that IL-6 inhibits HBV entry in
HepaRG cells and PHH through NTCP down-regulation. A previous
study aimed at identifying cytokines which could interfere with
in vitro HBV infection of HepaRG cells failed to recognize IL-6 as an
early step inhibitor (Watashi et al., 2013) since a 3 h pre-treatment
with a large panel of cytokines did not show any inhibitory activity
of IL-6. The experimental system used in our study was more likely
able to identify cytokines which could interfere with HBV entry
because a 3 days cytokine treatment was applied before HBV
infection. Indeed, we have shown that this prolonged cytokine
treatment was required in order to strongly reduce the surface
expression of NTCP, the HBV receptor. Since IL-6 drastically
suppressed NTCP mRNA within 1 day we speculate that the delay
required for suppression of the NTCP-mediated taurocholate
transport was related to the stability of this transporter in HepaRG
cells and furthermore in PHH. The fact that IL-6 has been
previously shown to more markedly reduce NTCP mRNA levels
than NTCP protein expression and sodium-dependent taurocho-
late uptake in PHH exposed to 10 ng/ml IL-6 for 48 h (Le Vee et al.,
2009b) fully supports this conclusion. In the same way, down-
regulation of NTCP expression in HepaRG cells in response to a
24 h exposure to 1 ng/ml IL-1β was more marked for mRNA levels
than for NTCP protein expression and for NTCP-related taurocho-
late transport (Le Vee et al., 2008), thus conﬁrming that the
repressing effect of cytokines towards NTCP-related bile acid
transport and NTCP protein expression is rather delayed when
compared to that toward NTCP mRNA levels, most likely owing to
NTCP protein turnover. The similar discordance in the level of
NTCP down-regulation between mRNA expression and sodium-
dependent taurocholate uptake activity in human hepatic cells
exposed to oncostatin M (Le Vee et al., 2011) or hepatocyte growth
factor (Le Vee et al., 2009a) also argues in favor of this conclusion.
We show that the IL-6 HBV entry inhibition is reversible and
consequently is not a result of cell apoptosis in agreement with the
absence of detectable cytotoxicity after IL-6 treatment. Of interest
is the observation from other studies that IL-6/STAT-3 pathway is
essential for liver regeneration and inhibits hepatocyte apoptosis
(Cressman et al., 1995; Tiberio et al., 2008). The reversibility of the
IL-6 pre-treatment and more importantly the full reversibility of
an IL-6 treatment applied post-infection strongly argue against a
direct role of IL-6 on the cccDNA form of HBV. This negative result
should be compared to the recently reported cytokine-dependent
degradation of HBV cccDNA mediated by APOBEC3B (Lucifora
et al., 2014).
Interestingly, we also demonstrate that HBV infection could be
efﬁciently inhibited without complete impairment of bile salt trans-
portation. Such data suggest that in vivo IL-6 treatment may inhibit
HBV infection without concomitant induction of a cholestatic process.
Further studies are however likely required to characterize the
potential relevance of IL-6 administration for blocking in vivo HBV
infection and to evaluate eventual adverse effects.
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Several in vivo and in vitro studies have indicated that exposure
to IL-1β, TNF-α, OSM and IL-6 markedly down regulated NTCP
expression (Le Vee et al., 2011, 2009b, 2008), but cellular and
molecular regulatory pathways by which IL-6 affects NTCP expres-
sion remain to be determined. Regulation of NTCP expression by
IL-6 has mainly been studied in rodents. These studies showed
that down regulation of NTCP could be mediated by activation of
cJun-N-terminal kinases (JNK) leading to a decrease in expression
and binding activity of multiple nuclear factors such as HNF1α,
HNF4α and the nuclear receptor dimer RXR: RAR as reviewed
(Geier et al., 2007). Unfortunately, no such studies on human cells
are available in the literature. Nevertheless, it seems that NTCP
transcriptional regulation in humans differs considerably from
that of rats because none of these nuclear factors activated the
promoter region of human NTCP (Jung et al., 2004). Characteriza-
tion of the mechanism by which IL-6 suppresses NTCP expression
in HepaRG cells or PHH therefore likely requires additional studies.
We have observed that NTCP expressed after transduction by a
lentiviral vector led to a slight increase of viral infection compared
to the large increase of taurocholate uptake, this could be
explained by the limited availability of cellular cofactors required
for HBV entry. In addition some cells present in the culture are not
differentiated in hepatocyte but transduced by the lentivirus and
are likely able to express functional NTCP but remain refractory to
HBV infection due to the lack of hepatocyte differentiation. More
importantly no more inhibition of HBV infection could be detected
after IL-6 pre-treatment in NTCP transduced cells, demonstrating
that the sole effect of IL-6 on viral entry was related to the
endogenous NTCP expression inhibition.
All in all, our results will provide important information to
better understand the role of IL-6 in the course of HBV infection,
and open a door to investigate in the antiviral role of cyto-
kines in inhibiting HBV entry. Since an increase of plasma IL-6
concentration has been consistently reported either in fulminant,
acute or chronic HBV infection (Pan et al., 2012; Sekiyama et al.,
1994; Wu et al., 2014) IL-6 could contribute in vivo to the control of
HBV infection. This control would result not only from interference
with HBV transcription (Hösel et al., 2009) and viral DNA replica-
tion (Kuo et al., 2009) but also from inhibition of viral entry. Given
the suspected role of IL-6 in controlling HBV infection in chronic
hepatitis B, if IL-6 is blocked for therapeutic purposes, the clinical
course of hepatitis B should be carefully monitored. Nevertheless,
to date no reports have described hepatitis reactivation after such
treatments (Kishida et al., 2011) suggesting that in most cases
control of HBV infection depends on several redundant mechan-
isms including the action of multiples inﬂammatory cytokines.
Materials and methods
Chemicals and reagents
Recombinant human IL-6 was provided by R&D Systems (Minnea-
polis, MN, USA). [3H (G) taurocholic acid (sp.act. 5 Ci/mmol) was
purchased from PerkinElmer Life and Analytical Sciences (Walthman,
MA, USA); HBsAg capture antibody was from Eurobio (Courtaboeuf,
Paris, France) and HBsAg detection antibody from Biorad (Marnes-la-
Coquette, Paris, France). Cell culture reagents were from Invitrogen
(Saint Aubin, France) or (Sigma-Aldrich, Saint Quentin Fallavier, France).
Cell culture
Human hepatoma HepaRG cells were cultured essentially as
previously described (Gripon et al., 2002). Brieﬂy cells were grown
in William's E medium supplemented with 5% fetal calf serum
(FCS), 2 mM Glutamine, 20IU/ml of penicillin, 20 mg/ml of strepto-
mycin and 5 mg/l insulin, 5 mM hydrocortisone hemisuccinate and
5 mg/ml sodium selenite. Cells were maintained in 5% CO2 atmo-
sphere at 37 1C. During the proliferation phase, culture medium
was renewed every 2 days for 3 weeks. For the differentiation
process, cells were maintained in the differentiation medium
described above supplemented with 2% DMSO for at least 2 more
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weeks in order to obtain conﬂuent differentiated cultures with
maximum functional activities.
Primary human hepatocytes (PHH) were obtained from adult
donors undergoing hepatic resection for primary and secondary
tumors, via the Biological Resource Center (Rennes, France). Cells
were cultured on plastic dishes in the differentiation medium used
for HepaRG cells. All experimental procedures complied with
French laws and regulations and were approved by the National
Ethics Committee.
HBV infection
HBV inoculumwas prepared from freshly collected supernatant
of pHBV-ΔEcoRI transfected HepG2 cells (Gripon et al., 1995).
HepG2 cells were maintained in the differentiation medium
supplemented with 10% FCS. The supernatants of transfected cells
were harvested every 3 days from day 5–14 post-transfection and
pooled. After elimination of cellular components by centrifugation
at 4600g for 30 min, viral particles were precipitated from the
culture supernatant with 6.6% polyethylene glycol (PEG) (Sigma-
Aldrich) for 16 h at 4 1C. After 30 min of centrifugation at 4600g
and 4 1C, particles aggregated in the pellet were solubilized in a
suspension medium (5% sorbitol, 1 mM EDTA, 10 mM Tris–HCl, pH
7.4) to concentrate them 50 fold and stored at 80 1C. Inoculation
of differentiated cells was performed with 10% inoculum in culture
medium containing 3% PEG 8000 for 16 h at 37 1C in 48 well
plates. At the end of the incubation period, cells were washed
thrice with William's E medium supplemented with 20 IU/ml of
penicillin, 20 mg/ml of streptomycin and cultured in the differen-
tiation medium.
Cell viability
Metabolically active viable cells were evaluated by the mito-
chondrial succinate dehydrogenase activity using an MTT assay.
Brieﬂy, after the culture medium was discarded, hepatocytes were
incubated for 3 h with 0.5 mg/ml MTT. After removal of the MTT,
formazan crystals were solubilized in isopropanol–HCl (0.05 N).
Using a microplate reader (Fluostar Omega, BMG Labtech), absor-
bance was directly measured at 560 nm. For each sample, values
from the 560 nm absorbance were substracted from those at
560 nm of blank to negate the background effect. The untreated
cell was considered 100% of viability.
NTCP transport assay
Bile acid transport due to NTCP was analyzed by measuring
sodium-dependent intracellular accumulation of the NTCP substrate
taurocholate. Brieﬂy, cells were incubated at 37 1C for 10 min with
40 nM [3H]taurocholate in the presence or absence of sodium. After
washing in phosphate buffered saline, cells were lyzed with 0.01 N
NaOH and accumulation of radiolabeled substrates was determined
through scintillation counting. Taurocholate accumulation values in
the presence of sodium minus accumulation values in the absence
of sodium, is thought to represent NTCP-mediated taurocholate-
transport (Noel et al., 2013).
HBsAg detection
Hepatitis B surface antigen (HBsAg) was detected in the culture
medium by ELISA (Enzyme-linked immunosorbent assay). The
HBsAg concentrationwas determined by comparisonwith a puriﬁed
solution of HBsAg of known concentration. The production of HBsAg
by infected cells at day 11 post-infection was used to evaluate
HBV entry.
RNA isolation and analysis
Total RNAs were isolated from cells using TRIzol reagent
(Invitrogen). RNAs were then subjected to reverse transcription
and real-time quantitative polymerase chain reaction (RTqPCR)
using the ﬂuorescent dye SYBR Green methodology and an ABI
Prism 7300 instrument (Invitrogen). Gene primers for NTCP were
as previously described (Le Vee et al., 2006). Relative quantiﬁca-
tion of the steady-state target mRNA levels was calculated after
normalization of the total amount of cDNA tested to a 18S RNA
endogenous reference.
Quantiﬁcation of HBV cccDNA by qPCR
HBV cccDNA (double-stranded DNA without nick and gap) was
quantiﬁed by real-time PCR as previously described (Werle-Lapostolle
et al., 2004) with modiﬁcations. In particular, speciﬁc primers for
cccDNA detection reported by Glebe et al. 2003 (ccc-1582F:
50-TGCACTTCGCTTCACCT-30; ccc-2316R: 50-GACCACCAAATGCCCCT-30)
were validated and used for cccDNA quantiﬁcation. Viral DNAs other
than cccDNA, including single-stranded and relaxed circular DNAs,
were degraded prior to ampliﬁcation by treatment of the DNA
templates with plasmid-safe adenosine triphosphate (ATP)-dependent
deoxyribonuclease DNase (Tebu bio-Le Perray en Yvelines, France). In
brief, HBV-infected cells were lysed for 2 h at 55 1C in the presence of
proteinase K (200 μg/ml), followed by 1M NaCl precipitation of
cellular genomic DNA and phenol–chloroform extraction of the super-
natant. A total of 250 ng of the extracted nucleic acids was digested
with 3 units of restriction enzyme (Nde1) (Biolabs-Evry-France), an
enzyme which does not cut HBV DNA but cuts once in plasmid pHBV-
ΔEcoRI and 1 unit plasmid-safe DNase for 4 h at 37 1C followed by
DNase inactivation. Ampliﬁcation of 735 bp cccDNA product was
conducted by denaturation at 95 1C for 10 min, followed by 45 cycles
of denaturation at 95 1C for 10 s, 60 1C annealing for 1 min, and 72 1C
elongation for 2 min. HBV cccDNA copy numbers were calculated with
a standard curve. Real-time PCR was performed using ﬂuorescent dye
SYBR Green methodology and an ABI Prism 7300 instrument.
NTCP plasmid construction and lentivirus production
A lentiviral vector was constructed for allowing the expression in
HepaRG differentiated cells of a fusion protein made of NTCP linked
by a P2A sequence which is expected to allow an efﬁcient separation
between the N terminal part and the C terminal part of a polypep-
tide (Kim et al., 2011) to the ﬂuorescent protein mCherry under the
control of a CMV promoter. This system allows the production of the
two polypeptides in equimolar amounts since they are translated
consecutively from the same mRNA; moreover the separation
between the two polypeptides was reported to nearly reach 100%.
The quantiﬁcation of the mCherry protein was then likely reﬂecting
the efﬁciency of cell transduction by the lentiviral construct and the
level of NTCP expression. The advantage of this P2A system over a
classical fusion protein between NTCP and mCherry lies within the
separation of the 2 polypeptides, thus preventing the impairment of
NTCP function by the presence of the fused ﬂuorescent protein.
Brieﬂy cDNA sequences were obtained from HepaRG RNAs after
reverse transcription (RT kit from Invitrogen); the cDNA correspond-
ing to the complete NTCP sequence was then ampliﬁed with Pfx50
DNA polymerase from Invitrogen, and a couple of NTCP speciﬁc
oligonucleotides containing Xba1 cloning site and a kozak sequence
for the forward primer (50ACCGACTCTAGAAGATCTGCCGCCACCATG-
GAGGCCCACAACGCGTCTGCC) and a P2A sequence and BamH1 site
for the reverse primer (50TCTAGAGGATCCCCCGGAAGGTCCAGGGTTCT
CCTCCACGTCTCCAGCCTGCTTCAGCAGGCTGAAGTTAGTAGCTCCGCTT-
CCCTCGAGGGCTGTGCAAGGGGAGCAGTCCTCC) (Sigma-Aldrich). The
ampliﬁed sequence was then introduced in the mCherry expressing
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vector (pLV mCherry) between Xba1 and BamH1 sites. The resulting
construct was termed pLV NTCP-P2A-mCherry. The vector was then
ampliﬁed in Escherichia coli, puriﬁed and sequenced. For the produc-
tion of lentiviral particles 3 plasmids (pSPAX2 (Addgene plasmid
12260, source D. Trono), phCMV G (Nègre et al., 2000), and pLVm-
Cherry (Addgene plasmid 36084, source P. Tsoulfas) or pLV NTCP-
P2A-mCherry) were co-transfected by calcium phosphate co-prec-
ipitation in HEK 293 SZ cells.
Statistical analysis
Data presented were acquired from a minimum of three
independent experiments. They are expressed as means7S.D.
Statistical analyses were performed with an unpaired student's t
test. All statistical analyses were performed with GraphPad Prism5
software (GraphPad Software, San Diego, CA, USA). Data were
considered signiﬁcantly different when po0.05.
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